423 related articles for article (PubMed ID: 25552403)
1. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy Increases the Renal Secretion of N
Bergagnini-Kolev MC; Hebert MF; Easterling TR; Lin YS
Drug Metab Dispos; 2017 Mar; 45(3):325-329. PubMed ID: 28069720
[TBL] [Abstract][Full Text] [Related]
3. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
[TBL] [Abstract][Full Text] [Related]
4. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine.
Müller F; König J; Hoier E; Mandery K; Fromm MF
Biochem Pharmacol; 2013 Sep; 86(6):808-15. PubMed ID: 23876341
[TBL] [Abstract][Full Text] [Related]
5. N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K).
Ito S; Kusuhara H; Kumagai Y; Moriyama Y; Inoue K; Kondo T; Nakayama H; Horita S; Tanabe K; Yuasa H; Sugiyama Y
Clin Pharmacol Ther; 2012 Nov; 92(5):635-41. PubMed ID: 23047651
[TBL] [Abstract][Full Text] [Related]
6. Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein-Mediated Drug-Drug Interactions in Healthy Volunteers.
Miyake T; Kimoto E; Luo L; Mathialagan S; Horlbogen LM; Ramanathan R; Wood LS; Johnson JG; Le VH; Vourvahis M; Rodrigues AD; Muto C; Furihata K; Sugiyama Y; Kusuhara H
Clin Pharmacol Ther; 2021 Feb; 109(2):507-516. PubMed ID: 32866300
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine.
Elsby R; Chidlaw S; Outteridge S; Pickering S; Radcliffe A; Sullivan R; Jones H; Butler P
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971610
[TBL] [Abstract][Full Text] [Related]
8. Elucidation of
Miyake T; Mizuno T; Takehara I; Mochizuki T; Kimura M; Matsuki S; Irie S; Watanabe N; Kato Y; Ieiri I; Maeda K; Ando O; Kusuhara H
Drug Metab Dispos; 2019 Nov; 47(11):1270-1280. PubMed ID: 31511257
[TBL] [Abstract][Full Text] [Related]
9. Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.
Grün B; Kiessling MK; Burhenne J; Riedel KD; Weiss J; Rauch G; Haefeli WE; Czock D
Br J Clin Pharmacol; 2013 Nov; 76(5):787-96. PubMed ID: 23305245
[TBL] [Abstract][Full Text] [Related]
10. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Topletz-Erickson AR; Lee AJ; Mayor JG; Rustia EL; Abdulrasool LI; Wise AL; Dailey B; DeChenne S; Walker LN; Alley SC; Endres CJ
J Clin Pharmacol; 2021 Apr; 61(4):461-471. PubMed ID: 32989831
[TBL] [Abstract][Full Text] [Related]
11. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y
J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731
[TBL] [Abstract][Full Text] [Related]
12. No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects.
Choi T; Komirenko AS; Riddle V; Kim A; Dhuria SV
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):818-826. PubMed ID: 30605260
[TBL] [Abstract][Full Text] [Related]
13. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
[TBL] [Abstract][Full Text] [Related]
14. Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine.
Shi R; Xu Z; Xu X; Jin J; Zhao Y; Wang T; Li Y; Ma Y
Eur J Pharm Sci; 2019 Jan; 127():282-290. PubMed ID: 30428337
[TBL] [Abstract][Full Text] [Related]
15. Investigation of non-linear Mate1-mediated efflux of trimethoprim in the mouse kidney as the mechanism underlying drug-drug interactions between trimethoprim and organic cations in the kidney.
Kito T; Ito S; Mizuno T; Maeda K; Kusuhara H
Drug Metab Pharmacokinet; 2019 Feb; 34(1):87-94. PubMed ID: 30528339
[TBL] [Abstract][Full Text] [Related]
16. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.
Stocker SL; Morrissey KM; Yee SW; Castro RA; Xu L; Dahlin A; Ramirez AH; Roden DM; Wilke RA; McCarty CA; Davis RL; Brett CM; Giacomini KM
Clin Pharmacol Ther; 2013 Feb; 93(2):186-94. PubMed ID: 23267855
[TBL] [Abstract][Full Text] [Related]
17. Renal Transporter-Mediated Drug-Biomarker Interactions of the Endogenous Substrates Creatinine and N
Türk D; Müller F; Fromm MF; Selzer D; Dallmann R; Lehr T
Clin Pharmacol Ther; 2022 Sep; 112(3):687-698. PubMed ID: 35527512
[TBL] [Abstract][Full Text] [Related]
18. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.
Xiao G; Rowbottom C; Boiselle C; Gan LS
Pharm Res; 2018 Jun; 35(8):159. PubMed ID: 29915999
[TBL] [Abstract][Full Text] [Related]
19. LC-MS/MS assay for N
Luo L; Kay J; Zhang J; Holliman CL; Rodrigues AD; Dowty M; Banfield C; Ramanathan R
Bioanalysis; 2018 May; 10(9):673-689. PubMed ID: 29749253
[TBL] [Abstract][Full Text] [Related]
20. Lack of Drug-Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers.
Chevalier C; Perrimond-Dauchy S; Dubourg J; Fouqueray P; Bolze S
Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):725-733. PubMed ID: 32860624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
